Nxera Pharma
Tracked across 9 events · 57 articles · First seen Apr 20, 2026 · Last active Sep 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Nxera Pharma joined the OpenFold consortium to enhance its AI-enabled drug discovery capabilities, particularly for GPCR targets, aligning with its strategy to improve R&D productivity and achieve its 2030 vision. This move is expected to strengthen its competitive position in the biopharmaceutical market.
Jun 10, 2026 · 9 articles
Business
Impact: Nxera reported strong Q2 results with revenue growth and profitability, driven by milestone payments and progress across its pipeline. The company's strategic partnerships and licensing deals position it for continued growth.
Aug 07, 2026 · 6 articles
Regulatory
Impact: Nxera is the originator of NBI-1117567 and will receive a US$10 million milestone payment, strengthening its financial position and validating its drug discovery platform.
Aug 26, 2026 · 6 articles
Business
Impact: Nxera is the recipient of the US$8.6 million milestone payment, which will be recognized as revenue in Q3 2026. This payment reflects progress in its collaboration and supports its drug discovery platform.
Sep 03, 2026 · 6 articles
Regulatory
Impact: Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.
Jun 02, 2026 · 6 articles
Tech
Impact: Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.
Jul 01, 2026 · 6 articles
Business
Impact: Nxera Pharma holds rights for Japan, South Korea, Australia, and New Zealand; not impacted by this expansion.
Jul 13, 2026 · 6 articles
Santhera Pharmaceuticals
licensee, investor
↔
Nxera Pharma
Nxera Pharma is a licensee of Santhera Pharmaceuticals, having acquired exclusiv
Santhera Pharmaceuticals
licensor, investee
↔
Nxera Pharma
Santhera Pharmaceuticals is the licensor of vamorolone to Nxera Pharma for speci
ERGEN INTELLIGENCE
Track Nxera Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard